RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All Swissmedic updates
Swissmedic
REGULATORY UPDATE
NAD+ supplements: When lifestyle products have criminal consequences
Published: 11/9/2026Detected: 11/9/2026

Summary preview

Highlights that misuse or illegal marketing of NAD+ “lifestyle” supplements may trigger criminal consequences, signaling a stricter enforcement posture against non-compliant products and claims.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
safety
labeling
manufacturing
clinical
#NAD+
#dietary supplement
#compliance
#labeling claims
#advertising

Official Source Document
Source Verified

Access the original document directly from SWISSMEDIC.

View Official Document

More from Swissmedic

  • Publication eCTD v4.0 Implementation Guide Package v2.011/9/2026
  • Save the Date: Clinical Trials Symposium 202711/4/2026
  • Submission of notifications of major changes via the Swissmedic Portal from 1 November 202611/2/2026
  • Additional information on the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”11/2/2026
  • Modification of the “Form DMF”11/1/2026

Get Swissmedic alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.